The payment codes, effective Feb. 11, are for bebtelovimab. The drug was authorized last week by the FDA to treat patients who are at high risk for progression to severe COVID-19 or hospitalization.
There are several new codes:
- Q0222: injection, bebtelovimab, 175 mg
- M0222: intravenous injection, bebtelovimab, including injection and post-administration monitoring
- M0223: intravenous injection, bebtelovimab, including injection and post-administration monitoring in the home or residence
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
